Patents by Inventor Styrbjörn Byström

Styrbjörn Byström has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom
    Publication number: 20230322807
    Abstract: Described herein is a process for the preparation of a compound of Formula I, wherein R1 and R2 each have the meanings provided in the description. Also described is a process for the preparation of pharmaceutically-active compounds including the process for the preparation of compounds of Formula I.
    Type: Application
    Filed: May 19, 2023
    Publication date: October 12, 2023
    Inventors: Jan Vågberg, Styrbjörn Byström
  • Process for the stereoselective preparation of chiral 2-[(hetero)arylalkylsulfanyl]pyrimidines and products obtainable therefrom
    Patent number: 11691988
    Abstract: Described herein is a process for the preparation of a compound of Formula I, wherein R1 and R2 each have the meanings provided in the description. Also described is a process for the preparation of pharmaceutically-active compounds including the process for the preparation of compounds of Formula I.
    Type: Grant
    Filed: October 14, 2022
    Date of Patent: July 4, 2023
    Assignee: Kancera AB
    Inventors: Jan Vågberg, Styrbjörn Byström
  • 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
    Patent number: 11660303
    Abstract: A compound of formula (I?) or (I?) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: May 30, 2023
    Assignee: KANCERA AB
    Inventors: Håkan Mellstedt, Styrbjörn Byström, Jan Vågberg, Elisabeth Olsson
  • A Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom
    Publication number: 20230068240
    Abstract: Described herein is a process for the preparation of a compound of Formula I, wherein R1 and R2 each have the meanings provided in the description. Also described is a process for the preparation of pharmaceutically-active compounds including the process for the preparation of compounds of Formula I.
    Type: Application
    Filed: October 14, 2022
    Publication date: March 2, 2023
    Inventors: Jan Vågberg, Styrbjörn Byström
  • Process for the steroselective preparation of chiral 2- [(hetero)arylalkylsulfanyl] pyrimidines and products obtainable therefrom
    Patent number: 11542281
    Abstract: Described herein is a process for the preparation of a compound of Formula I, wherein R1 and R2 each have the meanings provided in the description. Also described is a process for the preparation of pharmaceutically-active compounds including the process for the preparation of compounds of Formula I.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: January 3, 2023
    Assignee: KANCERA AB
    Inventors: Jan Vågberg, Styrbjörn Byström
  • Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1
    Patent number: 11339183
    Abstract: There is provided a compound of formula I, wherein R1, R2, Q1 and are as defined herein, which compounds are useful in the treatment of diseases and disorders associated with elevated levels of CX3CR1 and/or CX3CL1, in particular acute and/or chronic inflammation, eye diseases, lung diseases, skin diseases, joint and/or bone diseases, autoimmune diseases, cardiovascular diseases, metabolic diseases, brain diseases, neurodegenerative diseases, pain, cancer, liver diseases, kidney diseases, gastrointestinal diseases, human immunodeficiency virus and mood disorders.
    Type: Grant
    Filed: July 9, 2021
    Date of Patent: May 24, 2022
    Assignee: KANCERA AB
    Inventors: Jan Vågberg, Styrbjörn Byström, Elisabeth Olsson, Mattias Jönsson
  • PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1
    Publication number: 20210340167
    Abstract: There is provided a compound of formula I, wherein R1, R2, Q1 and are as defined herein, which compounds are useful in the treatment of diseases and disorders associated with elevated levels of CX3CR1 and/or CX3CL1, in particular acute and/or chronic inflammation, eye diseases, lung diseases, skin diseases, joint and/or bone diseases, autoimmune diseases, cardiovascular diseases, metabolic diseases, brain diseases, neurodegenerative diseases, pain, cancer, liver diseases, kidney diseases, gastrointestinal diseases, human immunodeficiency virus and mood disorders.
    Type: Application
    Filed: July 9, 2021
    Publication date: November 4, 2021
    Inventors: Jan VÅGBERG, Styrbjörn BYSTRÖM, Elisabeth OLSSON, Mattias JÖNSSON
  • PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1
    Publication number: 20210292349
    Abstract: There is provided a compound of formula (I), wherein R1, R2, Q1 and formula (X) are as defined herein, which compounds are useful in the treatment of diseases and disorders associated with elevated levels of CX3CR1 and/or CX3CL1, in particular acute and/or chronic inflammation, eye diseases, lung diseases, skin diseases, joint and/or bone diseases, autoimmune diseases, cardiovascular diseases, metabolic diseases, brain diseases, neurodegenerative diseases, pain, cancer, liver diseases, kidney diseases, gastrointestinal diseases, human immunodeficiency virus and mood disorders.
    Type: Application
    Filed: July 5, 2019
    Publication date: September 23, 2021
    Inventors: Jan VÅGBERG, Styrbjörn BYSTRÖM, Elisabeth OLSSON, Mattias JÖNSSON
  • 2-PHENYLIMIDAZO[4,5-B]PYRIDIN-7-AMINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY
    Publication number: 20210267994
    Abstract: A compound of formula (I?) or (I?) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.
    Type: Application
    Filed: April 30, 2021
    Publication date: September 2, 2021
    Inventors: Håkan MELLSTEDT, Styrbjörn BYSTRÖM, Jan VÅGBERG, Elisabeth OLSSON
  • A Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom
    Publication number: 20210188873
    Abstract: Described herein is a process for the preparation of a compound of Formula I, wherein R1 and R2 each have the meanings provided in the description. Also described is a process for the preparation of pharmaceutically-active compounds including the process for the preparation of compounds of Formula I.
    Type: Application
    Filed: May 15, 2019
    Publication date: June 24, 2021
    Inventors: Jan Vågberg, Styrbjörn Byström
  • 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
    Patent number: 11008318
    Abstract: Compound of formula (I?) or (I?) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: May 18, 2021
    Assignee: KANCERA AB
    Inventors: Håkan Mellstedt, Styrbjörn Byström, Jan Vågberg, Elisabeth Olsson
  • 2-PHENYLIMIDAZO[4,5-B]PYRIDIN-7-AMINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY
    Publication number: 20200024272
    Abstract: Compound of formula (I?) or (I?) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.
    Type: Application
    Filed: July 10, 2017
    Publication date: January 23, 2020
    Inventors: Håkan MELLSTEDT, Styrbjörn BYSTRÖM, Jan VÅGBERG, Elisabeth OLSSON
  • Novel compounds
    Publication number: 20100022590
    Abstract: The present invention relates to novel isoxazole compounds of formula (I), and pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides thereof, which are modulators of 11?-hydroxysteroid dehydrogenase type 1 (11?-HSD1). The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the preparation of a medicament for the treatment of glaucoma.
    Type: Application
    Filed: January 15, 2009
    Publication date: January 28, 2010
    Applicant: BIOVITRUM AB (publ.)
    Inventors: Styrbjörn Byström, Martin Haraldsson, Lars Johansson, Jan Tejbrant
  • Compounds
    Patent number: 6498182
    Abstract: The present invention is directed to compounds of formula I, formula Ia, and formula Ib. wherein each of R1, R2, R3, R4, Ra, and Rb has been defined herein. The invention is also directed to a process for the preparation, the use and pharmaceutical compositions comprising the compounds described above. These novel compounds are useful in therapy, particularly for the treatment of type 2 diabetes.
    Type: Grant
    Filed: September 26, 2001
    Date of Patent: December 24, 2002
    Assignee: Biovitrum AB
    Inventors: Styrbjörn Byström, Stephen James, Charlotta Liljebris